Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
1,558 questions in 115 reviews · Vascular
current versionsNo studies 346 · 22.2%Ungraded 90 · 5.8%Very low 281 · 18%Low 477 · 30.6%Moderate 313 · 20.1%High 51 · 3.3%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Intervention NR Time to hemostasis (seconds) · vascular surgery patients who undergo creation of an anastomosis The role of sealants for achieving anastomotic hemostasis in vascular surgery (2024) · Cochrane | no estimate extracted | 7 studies · 498 participants | Low |
Intervention NR Failure of hemostatic intervention ( · vascular surgery patients who undergo creation of an anastomosis The role of sealants for achieving anastomotic hemostasis in vascular surgery (2024) · Cochrane | RR 0.46 [0.35, 0.61] | 17 studies · 2120 participants | Very low |
Intervention NR Intraoperative blood loss (mL) · vascular surgery patients who undergo creation of an anastomosis The role of sealants for achieving anastomotic hemostasis in vascular surgery (2024) · Cochrane | no estimate extracted | 3 studies · 266 participants | Low |
Intervention NR Operating time (minutes) · vascular surgery patients who undergo creation of an anastomosis The role of sealants for achieving anastomotic hemostasis in vascular surgery (2024) · Cochrane | no estimate extracted | 4 studies · 436 participants | Low |
Intervention NR Death from bleeding complications (up to 30 days · vascular surgery patients who undergo creation of an anastomosis The role of sealants for achieving anastomotic hemostasis in vascular surgery (2024) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Postoperative bleeding (up to 30 days · vascular surgery patients who undergo creation of an anastomosis The role of sealants for achieving anastomotic hemostasis in vascular surgery (2024) · Cochrane | RR 0.78 [0.59, 1.04] | 9 studies · 1216 participants | Low |
Intervention NR Unplanned return to the operating room (up to 30 days · vascular surgery patients who undergo creation of an anastomosis The role of sealants for achieving anastomotic hemostasis in vascular surgery (2024) · Cochrane | RR 0.27 [0.04, 1.69] | 8 studies · 721 participants | Low |
Intervention NR Change in absolute walking distance from baseline (m) · people with intermittent claudication Mobile health technologies to improve walking distance in people with intermittent claudication (2024) · Cochrane | no estimate extracted | 2 studies · 503 participants | Low |
Intervention NR Change in claudication distance from baseline (m) · people with intermittent claudication Mobile health technologies to improve walking distance in people with intermittent claudication (2024) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Amputation‐free survival · people with intermittent claudication Mobile health technologies to improve walking distance in people with intermittent claudication (2024) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Revascularisation‐free survival · people with intermittent claudication Mobile health technologies to improve walking distance in people with intermittent claudication (2024) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Major adverse cardiovascular events (MACE) · people with intermittent claudication Mobile health technologies to improve walking distance in people with intermittent claudication (2024) · Cochrane | RR 1.37 [0.07, 28.17] | 1 study · 305 participants | Low |
Intervention NR Major adverse limb events (MALE) · people with intermittent claudication Mobile health technologies to improve walking distance in people with intermittent claudication (2024) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Above‐ankle amputation · people with intermittent claudication Mobile health technologies to improve walking distance in people with intermittent claudication (2024) · Cochrane | no estimate extracted | NR | No studies |
Supervised exercise therapy following vascular intervention vs vascular intervention alone MWD ‐ change from baseline · people with symptomatic peripheral arterial disease§ Effects of additional exercise therapy after a successful vascular intervention for people with symptomatic… (2024) · Cochrane | no estimate extracted | 2 studies · 89 participants | Very low |
Supervised exercise therapy following vascular intervention vs vascular intervention alone 6MWT ‐ change from baseline · people with symptomatic peripheral arterial disease§ Effects of additional exercise therapy after a successful vascular intervention for people with symptomatic… (2024) · Cochrane | no estimate extracted | 1 study · 49 participants | Very low |
Supervised exercise therapy following vascular intervention vs vascular intervention alone PFWD ‐ change from baseline · people with symptomatic peripheral arterial disease§ Effects of additional exercise therapy after a successful vascular intervention for people with symptomatic… (2024) · Cochrane | no estimate extracted | 2 studies · 87 participants | Very low |
Supervised exercise therapy following vascular intervention vs vascular intervention alone ABI ‐ absolute value · people with symptomatic peripheral arterial disease§ Effects of additional exercise therapy after a successful vascular intervention for people with symptomatic… (2024) · Cochrane | no estimate extracted | 2 studies · 110 participants | Very low |
Supervised exercise therapy following vascular intervention vs vascular intervention alone Mortality · people with symptomatic peripheral arterial disease§ Effects of additional exercise therapy after a successful vascular intervention for people with symptomatic… (2024) · Cochrane | OR 0.92 [0.42, 2] | 6 studies · 346 participants | Very low |
Supervised exercise therapy following vascular intervention vs vascular intervention alone Quality of life SF‐36 Physical component absolute score · people with symptomatic peripheral arterial disease§ Effects of additional exercise therapy after a successful vascular intervention for people with symptomatic… (2024) · Cochrane | no estimate extracted | 2 studies · 105 participants | Very low |
Supervised exercise therapy following vascular intervention vs vascular intervention alone Reintervention · people with symptomatic peripheral arterial disease§ Effects of additional exercise therapy after a successful vascular intervention for people with symptomatic… (2024) · Cochrane | OR 0.91 [0.23, 3.65] | 5 studies · 252 participants | Very low |
Remote ischaemic preconditioning (RIPC) vs no RIPC Perioperative mortality (within 1 month after operation) · people undergoing elective major vascular surgery Remote ischaemic preconditioning versus no remote ischaemic preconditioning for vascular and endovascular… (2023) · Cochrane | RR 1.41 [0.59, 3.4] | 10 studies · 965 participants | Moderate |
Remote ischaemic preconditioning (RIPC) vs no RIPC Myocardial infarction (within 1 month after operation) · people undergoing elective major vascular surgery Remote ischaemic preconditioning versus no remote ischaemic preconditioning for vascular and endovascular… (2023) · Cochrane | RR 0.82 [0.49, 1.4] | 11 studies · 1001 participants | Moderate |
Remote ischaemic preconditioning (RIPC) vs no RIPC Renal impairment (within 1 month after operation) · people undergoing elective major vascular surgery Remote ischaemic preconditioning versus no remote ischaemic preconditioning for vascular and endovascular… (2023) · Cochrane | RR 1.07 [0.62, 1.86] | 12 studies · 1054 participants | Moderate |
Remote ischaemic preconditioning (RIPC) vs no RIPC Stroke (within 1 month after operation) · people undergoing elective major vascular surgery Remote ischaemic preconditioning versus no remote ischaemic preconditioning for vascular and endovascular… (2023) · Cochrane | RR 0.33 [0.04, 3.15] | 4 studies · 392 participants | Moderate |
Remote ischaemic preconditioning (RIPC) vs no RIPC Hospital stay · people undergoing elective major vascular surgery Remote ischaemic preconditioning versus no remote ischaemic preconditioning for vascular and endovascular… (2023) · Cochrane | no estimate extracted | 7 studies · 569 participants | Moderate |
Remote ischaemic preconditioning (RIPC) vs no RIPC Limb loss (within 1 month after operation) · people undergoing elective major vascular surgery Remote ischaemic preconditioning versus no remote ischaemic preconditioning for vascular and endovascular… (2023) · Cochrane | RR 0.74 [0.05, 10.61] | 3 studies · 322 participants | Low |
Remote ischaemic preconditioning (RIPC) vs no RIPC Operating time or total anaesthetic time · people undergoing elective major vascular surgery Remote ischaemic preconditioning versus no remote ischaemic preconditioning for vascular and endovascular… (2023) · Cochrane | no estimate extracted | 10 studies · 803 participants | Moderate |
Totally percutaneous vs cut‐down femoral artery access Short‐term mortality (30‐day or in‐hospital) · people undergoing elective bifurcated abdominal endovascular aneurysm repair Totally percutaneous versus surgical cut‐down femoral artery access for elective bifurcated abdominal… (2023) · Cochrane | RR 1.5 [0.06, 36.18] | 2 studies · 181 participants | Low |
Totally percutaneous vs cut‐down femoral artery access Failure of aneurysm exclusion( · people undergoing elective bifurcated abdominal endovascular aneurysm repair Totally percutaneous versus surgical cut‐down femoral artery access for elective bifurcated abdominal… (2023) · Cochrane | RR 0.17 [0.01, 4.02] | 1 study · 151 participants | Moderate |
Totally percutaneous vs cut‐down femoral artery access Wound infection (30‐day or in‐hospital) · people undergoing elective bifurcated abdominal endovascular aneurysm repair Totally percutaneous versus surgical cut‐down femoral artery access for elective bifurcated abdominal… (2023) · Cochrane | RR 0.18 [0.01, 3.59] | 3 studies · 318 participants | Moderate |
Totally percutaneous vs cut‐down femoral artery access Major complications (30‐day or in‐hospital) · people undergoing elective bifurcated abdominal endovascular aneurysm repair Totally percutaneous versus surgical cut‐down femoral artery access for elective bifurcated abdominal… (2023) · Cochrane | RR 1.21 [0.61, 2.41] | 3 studies · 318 participants | Moderate |
Totally percutaneous vs cut‐down femoral artery access Medium‐ to long‐term complications( · people undergoing elective bifurcated abdominal endovascular aneurysm repair Totally percutaneous versus surgical cut‐down femoral artery access for elective bifurcated abdominal… (2023) · Cochrane | RR 0.82 [0.25, 2.65] | 1 study · 135 participants | Moderate |
Totally percutaneous vs cut‐down femoral artery access Bleeding complications (30‐day or in‐hospital) · people undergoing elective bifurcated abdominal endovascular aneurysm repair Totally percutaneous versus surgical cut‐down femoral artery access for elective bifurcated abdominal… (2023) · Cochrane | RR 1.02 [0.29, 3.64] | 2 studies · 181 participants | Moderate |
Totally percutaneous vs cut‐down femoral artery access Operating time (minutes) · people undergoing elective bifurcated abdominal endovascular aneurysm repair Totally percutaneous versus surgical cut‐down femoral artery access for elective bifurcated abdominal… (2023) · Cochrane | no estimate extracted | 3 studies · 318 participants | Low |
Physical exercise vs no treatment Intensity of disease signs and symptoms: VCSS Scale: 0 to 30 (lower is better) · people with non‐ulcerated chronic venous insufficiency Physical exercise for the treatment of non‐ulcerated chronic venous insufficiency (2023) · Cochrane | no estimate extracted | 2 studies · 49 participants | Very low |
Physical exercise vs no treatment Ejection fraction · people with non‐ulcerated chronic venous insufficiency Physical exercise for the treatment of non‐ulcerated chronic venous insufficiency (2023) · Cochrane | MD 4.88 | 1 study · 28 participants | Very low |
Physical exercise vs no treatment Venous refilling time · people with non‐ulcerated chronic venous insufficiency Physical exercise for the treatment of non‐ulcerated chronic venous insufficiency (2023) · Cochrane | MD 10.7 | 3 studies · 72 participants | Very low |
Physical exercise vs no treatment Incidence of venous leg ulcer · people with non‐ulcerated chronic venous insufficiency Physical exercise for the treatment of non‐ulcerated chronic venous insufficiency (2023) · Cochrane | no estimate extracted | NR | No studies |
Physical exercise vs no treatment Quality of life VEINES‐QOL/SF‐36/CIVIQ‐20 (lower is better) · people with non‐ulcerated chronic venous insufficiency Physical exercise for the treatment of non‐ulcerated chronic venous insufficiency (2023) · Cochrane | MD 4.6 | 2 studies · 61 participants | Very low |
Physical exercise vs no treatment Exercise capacity assessed by: time on treadmill (higher is better) · people with non‐ulcerated chronic venous insufficiency Physical exercise for the treatment of non‐ulcerated chronic venous insufficiency (2023) · Cochrane | MD 77.74 | 2 studies · 56 participants | Very low |
Physical exercise vs no treatment Muscle strength assessed by: heel lifts (higher is better) · people with non‐ulcerated chronic venous insufficiency Physical exercise for the treatment of non‐ulcerated chronic venous insufficiency (2023) · Cochrane | MD 3.1 | 3 studies · 89 participants | Very low |
Oral DTIs vs conventional anticoagulation Recurrent VTE (7 months) · participants with diagnosed DVT Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the… (2023) · Cochrane | OR 1.17 [0.83, 1.65] | 3 studies · 5994 participants | Moderate |
Oral factor Xa inhibitors vs conventional anticoagulation Non‐fatal PE (3 to 12 months) · participants with diagnosed DVT Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the… (2023) · Cochrane | OR 0.93 [0.68, 1.27] | 7 studies · 15166 participants | Moderate |
Oral factor Xa inhibitors vs conventional anticoagulation All‐cause mortality (3 to 6 months) · participants with diagnosed DVT Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the… (2023) · Cochrane | OR 0.87 [0.67, 1.14] | 9 studies · 10770 participants | Moderate |
Oral factor Xa inhibitors vs conventional anticoagulation Major bleeding (3 to 12 months) · participants with diagnosed DVT Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the… (2023) · Cochrane | OR 0.63 [0.45, 0.89] | 17 studies · 18066 participants | High |
Oral DTIs vs conventional anticoagulation Recurrent DVT (7 months) · participants with diagnosed DVT Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the… (2023) · Cochrane | OR 1.11 [0.74, 1.66] | 3 studies · 5994 participants | Moderate |
Oral DTIs vs conventional anticoagulation Fatal PE (7 months) · participants with diagnosed DVT Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the… (2023) · Cochrane | OR 1.32 [0.29, 6.02] | 3 studies · 5994 participants | Moderate |
Oral DTIs vs conventional anticoagulation Non‐fatal PE (7 months) · participants with diagnosed DVT Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the… (2023) · Cochrane | OR 1.29 [0.64, 2.59] | 3 studies · 5994 participants | Moderate |
Oral DTIs vs conventional anticoagulation All‐cause mortality (7 months) · participants with diagnosed DVT Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the… (2023) · Cochrane | OR 0.66 [0.41, 1.08] | 1 study · 2489 participants | Moderate |